Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19578086 | 0.81 | NPC1 (0.39) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL22121782 | 0.79 | NPC1 (0.34) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL137744 | 0.79 | NPC1 (0.37) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL25311795 | 0.76 | NPC1 (0.38) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL16265142 | 0.76 | NPC1 (0.35) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL477179 | 0.75 | KDM4E (0.36) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL25310605 | 0.73 | NPC1 (0.37) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL19554501 | 0.73 | NPC1 (0.43) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL1202660 | 0.69 | GAA (0.43) | — | |
| SCHEMBL25311635 | 0.69 | MAPT (0.39) | NPC1RAB9AHPGDSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | NPC1 4572/4885RAB9A 2293/4885HPGD 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.